Biogen Inc. vs Eli Lilly & Co.
BIIB vs LLY — side-by-side comparison from reported financials. BIIB leads 3, LLY leads 7 of 10 comparable metrics.
Biogen Inc.
BIIB · Healthcare
$225.71+3.33%Strained
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | BIIB | LLY |
|---|---|---|
| Price | $225.71 | $1 177.20 |
| Market cap | $33.4B | $1.05T |
| Revenue (TTM) | $10.0B | $79.7B |
| Revenue growth | -0.9% | +31.7% |
| Net margin | 8.3% | 33.5% |
| Free cash flow | $2.70B | $18.2B |
| Net cash (debt) | $807M | ($35.2B) |
| 1-year price return | +50.9% | +37.6% |
| P/E | 40.0 | 41.6 |
| P/E vs own history (cheap-side %) | 1% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 5% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 8 of 10 | 11 of 10 |
| Employees | 7,500 | 50,000 |
Full résumé-style profiles: BIIB CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.